Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size by Type, End User, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2034
Overview
The Non-alcoholic Steatohepatitis (NASH) Biomarkers Market size was valued at USD 2.08 Billion in 2025 and the total Non-alcoholic Steatohepatitis (NASH) Biomarkers revenue is expected to grow at a CAGR of 30.2% from 2026 to 2034, reaching nearly USD 22.39 Billion.
Nonalcoholic steatohepatitis (NASH) is the active form of Nonalcoholic fatty liver disease (NAFLD), with hepatic necroinflammation and faster fibrosis progression. The unwanted fat deposition in liver is the key cause of this disease. If left untreated or undiagnosed, it can lead to liver cirrhosis and ultimately progress to liver failure.
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Growth Outlook
To know about the Research Methodology :- Request Free Sample Report
The high incidence of liver-related diseases has encourage some industry players and research institutes to spend in development of sophisticated NASH diagnostic and therapeutic products.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
The scope of the report includes a detailed study of global and regional markets for Non-alcoholic Steatohepatitis (NASH) Biomarkers with the reasons given for variants in the growth of the industry in certain regions.
The prevalence of NASH is rising at a shocking rate and thus has directed to the increasing need for effective diagnostic tools in recent years. The NASH Education Program reported that, the incidence of NASH is expected to increase by 30.2% during 2025 to 2034. The rising incidence of diabetes and obesity, increasing demand for non-invasive tests, and increasing public and private sector initiatives to upsurge awareness about NASH are anticipated to drive the growth of the market. Apart from this, the negative regulatory scenario is expected to affect market growth during forecast period. For example, the existence of stringent regulations by the US FDA for the limitation of biomarkers is expected to restrict the market growth.
The report on Non-alcoholic Steatohepatitis (NASH) Biomarkers market covers segments such as Marker Type, End User and Region. The Marker Type segment includes Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others. Among the Marker Type, Serum Biomarkers is accounted for the largest 30.2% market share in the Non-alcoholic Steatohepatitis (NASH) Biomarkers market, due to their indirect relation with NASH. The Hepatic fibrosis markers are anticipated to raise exponentially during forecasted period due to their more accuracy and efficiency.
This marker type segment is anticipated to hold the leading share of NASH biomarkers market by 2034 The End User segment is further sub-segmented into Pharmaceutical Companies and CROs, Research Institutes and Academics, Hospitals & Clinics, Diagnostic Centers, and Others. Because of the necessity of non-invasive diagnostic tools for routine observing of drug therapy efficiency in the course of clinical trial of drug candidates, the Pharmaceutical Companies and CROs end-user segment is anticipated to have a reasonable growth during the forecasted period.
Based on regional segment, the Non-alcoholic Steatohepatitis (NASH) Biomarkers market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to hold leading position in the Non-alcoholic Steatohepatitis (NASH) Biomarkers market throughout the forecast period. Growth of this particular region is ascribed to the encouraging government initiatives, the presence of sophisticated healthcare amenities, and increasing incidence of diabetes, fatty liver disease, and obesity. Europe is expected to hold the second position in the non-alcoholic steatohepatitis (NASH) biomarkers market.
The factors like growing prevalence of NASH, rising incidence of obesity and diabetics, existence of well-established healthcare sector, and growing research and development on liver diseases. The market growth in the Asia-Pacific region can be ascribed to factors like the existence of a large patient base, rise in healthcare spending, and availability of skilled healthcare personnel. The Middle East and Africa is expected to register the lowest share in the global market. In the African region, the market is expected to be negatively affected by factors like poor healthcare amenities, a smaller amount disposable income, inadequate awareness about liver diseases, including NASH.
Key players operating in the Non-alcoholic Steatohepatitis (NASH) Biomarkers market are BioPredictive, Celerion, Cisbio, Echosens, Enterome, GENFIT, Laboratory Corporation of America Holdings, NGM Biopharmaceuticals, One Way Liver, SL, Pacific Biomarkers, Prometheus Laboratories Inc., Perspectrum Diagnostics Ltd, Quest Diagnostics, Regulus Therapeutics, Inc., Siemens Healthineers, Shenzhen New Industries Biomedical Engineering Co., Ltd, Xeptagen SpA, and Exalenz Biosciences Ltd.
In November 2018, Siemens Healthineers declared that the US Food and Drug Administration (FDA) had approved an innovative device designation for its ELF test. In September 2018, Quest Diagnostics associated with Houston Healthcare to provide advanced laboratory services. With this, the company aims to brace its position in the market. Similar kind of strategies followed by the other players functioning in the non-alcoholic steatohepatitis biomarkers market were innovation, product development, acquisition, and expansion.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Non-alcoholic Steatohepatitis (NASH) Biomarkers market dynamics, structure by identifying and analyzing the market segments and project the global market size.
Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Non-alcoholic Steatohepatitis (NASH) Biomarkers market.
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Recent Development
| Date | Company | Development | Impact |
|---|---|---|---|
| 05 May 2026 | HepQuant | Presented clinical data at Digestive Disease Week 2026 showing the HepQuant DuO® test outperforms standard scores in predicting esophageal varices. | Validates the non-invasive blood-based test as a superior diagnostic tool for assessing liver health and fibrosis severity. |
| 15 August 2025 | Novo Nordisk | Received FDA approval for Wegovy to treat patients diagnosed with MASH (Metabolic Dysfunction-Associated Steatohepatitis) and moderate-to-advanced fibrosis. | Drives significant demand for companion diagnostic biomarkers to identify and monitor eligible patients for metabolic liver therapy. |
| 30 September 2025 | HepQuant | Showcased the HepQuant DuO™ platform's efficacy in quantifying liver function and physiology at the 9th Annual MASH Drug Development Summit. | Enhances the utility of quantitative biomarkers in clinical trial design for emerging MASH/NASH therapeutics. |
| 13 December 2025 | HepQuant | Presented research at the MASH-TAG conference confirming the ability of their biomarkers to track disease progression and treatment impact. | Strengthens the clinical adoption of non-invasive diagnostics over traditional liver biopsy for long-term patient monitoring. |
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Scope: Inquire before buying
| Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 2.08 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 30.2% | Market Size in 2034: | USD 22.39 Bn. |
| Segments Covered: | by Type | Serum Biomarkers Hepatic Fibrosis Biomarkers Apoptosis Biomarkers Oxidative Stress Biomarkers Others |
|
| by End User | Pharmaceutical Companies and CROs Research Institutes and Academics Hospitals & Clinics Diagnostic Centers Others. |
||
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, Key Players are
1. BioPredictive, Celerion
2. Cisbio
3. Echosens
4. Enterome
5. GENFIT SA
6. Laboratory Corporation of America Holdings
7. NGM Biopharmaceuticals
8. One Way Liver SL
9. Pacific Biomarkers
10. Prometheus Laboratories Inc.
11. Perspectrum Diagnostics Ltd.
12. Quest Diagnostics
13. Regulus Therapeutics, Inc.
14. Siemens Healthineers
Frequently Asked questions
1. What was the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market size in 2025?
Ans: The Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market size was USD 2.08 Billion in 2025.
2. What are the different segments of the Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market?
Ans. The Global market is divided into Type and End User.
3. What is the study period of this market?
Ans. The Global market will be studied from 2020 to 2034.
4. Which region is expected to hold the highest Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market share?
Ans. The North America dominates the market share in the market.
5. What is the Forecast Period of Global market?
Ans. The Forecast Period of the market is 2026-2034 in the market.